Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Multiple Myeloma trials

The registry lists 29 Multiple Myeloma studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 1 are open to participants now and 15 have results posted.

Early Phase 1 3Phase 1 10Phase 2 17Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
• Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete RemissionTerminatedNCT03376477Phase 2Results posted
• MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple MyelomaTerminatedNCT03218163Phase 2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk MyelomaCompletedNCT01858558Phase 2Results posted
• Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple MyelomaTerminatedNCT01374217Phase 2Results posted
• Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete RemissionCompletedNCT01349569Phase 2Results posted
• Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple MyelomaCompletedNCT01045460Phase 2Results posted
• Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYCompletedNCT00809276Phase 1/2Results posted
• Activated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaCompletedNCT00566098Phase 1/2Results posted
• Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple MyelomaTerminatedNCT00470093Early Phase 1Results posted
• Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00445484Phase 2Results posted
• Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple MyelomaCompletedNCT00287872Phase 2Results posted
• Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple MyelomaCompletedNCT00258206Phase 2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple MyelomaCompletedNCT01861340Early Phase 1
• Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation CyclophosphamideCompletedNCT01342289Phase 1
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell TransplantTerminatedNCT00469820Phase 1
• Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
• Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
• Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00024466Phase 1/2
• MS-275 in Treating Patients With Hematologic CancerCompletedNCT00015925Phase 1
• Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00006042Phase 1
• Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003962Phase 1
• Donor Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003960Phase 2
• Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersCompletedNCT00003572Phase 2